Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 4/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 6/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904022 | 1.00 | TLR2 (0.33) | TLR2DPP4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL2904021 | 1.00 | TLR2 (0.33) | TLR2DPP4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL15321964 | 0.84 | MEN1 (0.32) | DPP4PDK2 | |
| SCHEMBL17632223 | 0.79 | CHRNB2 (0.35) | TLR2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL28866517 | 0.79 | CHRNB2 (0.35) | TLR2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL2569062 | 0.79 | DPP4 (0.39) | DPP4PDK2 | |
| SCHEMBL14780353 | 0.76 | CHRNB2 (0.37) | TLR2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL27324166 | 0.76 | ALDH1A1 (0.33) | DPP4 | |
| SCHEMBL19971695 | 0.72 | KDM5A (0.33) | DPP4 | |
| SCHEMBL19971696 | 0.72 | KDM5A (0.33) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | TLR2 3383/4885DPP4 180/4885CHRNB2 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.